China Medical Technologies Announces the Recent Publication of a Study on its SPR Analyzer and HPV DNA Chip in Cancer Genetics and Cytogenetics and the Creation of a Medical Publications Column to the Investor Relations Section on its Website

BEIJING, June 29 China Medical Technologies,Inc. (the "Company") (Nasdaq: CMED), a leading China-based advanced in-vitrodiagnostic ("IVD") company, today announced the recent publication of a largesample study on the Company's SPR analyzer and related HPV DNA chip (the "SPRSystem") for the detection of 16 high risk and 8 low risk genotypes of humanpapillomavirus ("HPV"). The study tested specimens of 560 patients withatypical squamous cells of undetermined significance ("ASCUS") or above usingthe SPR System and compared the results with sequence analysis. The studyconcluded that the SPR System is highly sensitive and specific in HPVgenotyping (99% concordance between the SPR System and sequence analysis) andcan become an effective approach for HPV genotyping in a clinical setting.

The study is entitled, "A Surface Plasmon Resonance-based System toGenotype Human Papillomavirus", and can be found in the online edition of themedical journal Cancer Genetics and Cytogenetics, Volume 200, Issue 2, athttp://cancergeneticsjournal.org .

The Company also announced the creation of a new column "MedicalPublications" in its investor relations section at http://ir.chinameditech.comwhich currently posts 12 articles from Chinese medical publications. Thearticles related to the use of the Company's FISH products in variousapplications including prenatal diagnosis, cancer detection and companiondiagnostic for targeted cancer drugs. The Company plans to update the columnperiodically to add medical publications related to the Company's productsfollowing approval from the authors.

About China Medical Technologies, Inc.

China Medical Technologies, Inc. is a leading China-based advanced IVDcompany using molecular diagnostic technologies including Fluorescent in situHybridization (FISH) and Surface Plasmon Resonance (SPR) and animmunodiagnostic technology, Enhanced Chemiluminescence Immunoassay (ECLIA),to develop, manufacture and distribute diagnostic products used for thedetection of various cancers, diseases and disorders as well as companiondiagnostic tests for targeted cancer drugs. The Company generates all of itsrevenues in China through the sale of diagnostic consumables including FISHprobes, SPR-based DNA chips and ECLIA reagent kits to hospitals which arerecurring users of the consumables for their patients. The Company sells FISHprobes and SPR chips to large hospitals through its direct sales force andECLIA reagent kits to small and mid-size hospitals through distributors. Formore information, please visit http://www.chinameditech.com .For more information, please contact: Winnie Yam Tel: +852-2511-9808 Email: [email protected]

SOURCE China Medical Technologies, Inc.